Back to top
more

Loncar Cancer Immunotherapy ETF: (CNCR)

(Delayed Data from NASDAQ) As of Jun 27, 2022 03:54 PM ET

 Add to portfolio

$15.57 USD

15.57
9,800

-0.10 (-0.78%)

Volume: 9,800

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

ETF Quote Details

Previous Close 15.63
Open 15.74
Bid 12.75
Ask 18.57
Day Low-High 15.35-15.75
52wk Low-High 12.76-32.99
Volume 9,800
NAV (month end) 13.90
Premium (+)/Discount (-) (month end)+1.73

Zacks Premium Research for CNCR

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

Hold 3
ETF Risk

Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.

High
ETF Snapshot

ETF Expense Ratio

Expense Ratio 0.79%
Dividend (Yield) $1.85 (11.86%)
Issuer LONCAR INVESTMENTS

Benchmark for CNCR

LONCAR CANCER IMMUNOTHERAPY INDEX

The Loncar Cancer Immunotherapy Index seeks to track the combined performance of a basket of companies that develop therapies to treat cancer by harnessing the bodys own immune system.

Fund Summary for CNCR

LONCAR CANCER IMMUNOTHERAPY ETF

The Loncar Cancer Immunotherapy ETF seeks to track the Loncar Cancer Immunotherapy Index.